In response to your request dated April 23, 2009 for access to any records or reports of post-market surveillance and scientific studies monitoring or evaluating the safety of DHASCO and ARASCO (DHA and ARA) in infant formula.

We have no responsive information in our files. FDA has never received any reports or studies regarding post-market surveillance or scientific studies monitoring or evaluating the safety of DHASCO and ARASCO (DHA and ARA) in infant formula.

Certain material has been deleted from the records furnished to you because of preliminary review of the records indicated that the deleted information is not required to be publicly disclosed and that disclosure is not appropriate. FDA has taken this approach to facilitate the process of responding to you. If you dispute FDA's preliminary determination and would like FDA to reconsider any particular deletion, please let us know in writing at the following address: Food and Drug Administration, Freedom of Information Staff, HFI-35, 5600 Fishers Lane, Rockville, MD 20857 within thirty days from date of this letter. If we do not receive a response in that time period we will consider the matter closed. If you do not request further consideration and the agency then formerly denies your request for any or all the previously withheld information, you will have the right to appeal that decision. Any letter of denial will explain how to make this appeal.

The following charges for this request to date may be included in a monthly invoice:

Reproduction $ 0 Search $ 0 Review $ 0 Other $ 0 Total $ 0

THE ABOVE TOTAL, MAY NOT REFLECT THE FINAL CHARGES FOR THIS REQUEST. DO NOT PAYMENT UNLESS YOU RECEIVED AN INVOICE.

Sincerely yours,

[Signature]

Himario R. Duncan
Paralegal Specialist
Executive Operations Staff
Center for Food Safety
and Applied Nutrition

NO Enclosure